Citi analyst Yigal Nochomovitz lowered the firm’s price target on ProQR Therapeutics to $2.25 from $3 and keeps a Neutral rating on the shares. The analyst cites dilution related to the expanded agreement with Lilly announced in December 2022 for the target drop.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRQR:
- ProQR Therapeutics management to meet with Cantor Fitzerald
- ProQR Therapeutics price target raised to $5 from $1.50 at H.C. Wainwright
- ProQR Therapeutics upgraded to Outperform from Market Perform at JMP Securities
- ProQR announces initial pipeline targets, highlights Axiomer platfotform
- ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event